BiomeSense delivers an end-to-end platform that automates gut-microbiome sample capture, processing, and AI-driven analysis—shrinking sample-to-insight costs and unlocking 30× richer longitudinal data for biomarker discovery and therapeutic development.
About the company
BiomeSense is building the data backbone for microbiome-powered precision medicine. Its GutLab smart-collection device installs directly in clinics, enabling daily, contact-free stool capture without manual handling. Automated lab workflows then convert raw samples into harmonized datasets at industrial scale, while proprietary machine-learning models mine those dense time-series data for predictive biomarkers and drug targets.
Strategic validation came when LabCorp ran side-by-side pilots and subsequently led BiomeSense’s seed round. Early studies have already surfaced biomarkers that predict HER2 therapy response and colorectal-cancer recurrence, signaling strong commercial pull from pharma and diagnostics partners. Because every new sample both lowers COGS and sharpens the algorithms, the platform compounds defensibility in the same way Illumina dominates genomics.
Why We Invested
Unlocking the potential of the human gut microbiome demands high-resolution, longitudinal data that traditional collection methods simply cannot deliver. BiomeSense closes this infrastructure gap with a vertically integrated stack: GutLab smart-collection hardware captures daily, hands-free samples; automated wet-lab robotics harmonize and sequence at industrial scale; and proprietary AI models transform those dense time-series into actionable biomarker insights. The result is a 10× drop in cost and 30× increase in usable data, accelerating therapeutic discovery and precision diagnostics.
As pharma and diagnostics players race to incorporate microbial signals into their pipelines, BiomeSense’s compounding data flywheel—every sample lowers COGS and sharpens algorithms—builds a moat reminiscent of genomics leaders. Early clinical collaborations have already surfaced biomarkers tied to immunotherapy response and cancer recurrence, validating real-world impact. Guided by founders with deep synthetic-biology and bioinformatics expertise, BiomeSense is poised to become the indispensable data layer powering the next wave of microbiome-driven medicine.